Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.06%
+14.86%
+0.23%
-3.80%
-3.18%
NVS
Novartis AG
$131.34
Strengths
Earnings are forecast to grow
Outperform the market
Expands stock buyback program
Risk Analysis
Downgraded on weak valued
Chart
$122.23 (+7.45%)
$116.66 (+12.58%)
$116.7 (+12.54%)
$109.38 (+20.08%)
NVS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
NVS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Rating
Rating
Downgraded on weak valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Outperform the market
NVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
NVS Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
NVS Earnings
The TTM reflects 12-month period, providing review of NVS financial performance.
The company financial health has moderately improved over the past year
Financial Score
PFE
24.85
+0.65%
AZN
83.22
-0.78%
MRK
87.62
+1.54%
SNY
49.66
-0.14%
LLY
799.57
-1.16%
What is NVS current stock price?
What are NVS stock strengths?
What risks are associated with NVS stock?
When is NVS next earnings report?
What is NVS market cap and volume?
What is NVS's current Stock IQ?
Should I buy NVS stock right now?
Is NVS a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVS?
What does a 'Strong Sell' rating mean for NVS?
What factors influence NVS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.06%
+14.86%
+0.23%
-3.80%
-3.18%
NVS
Novartis AG
Current Price
$131.34
Stock Insights
Strengths
Earnings are forecast to grow
Outperform the market
Expands stock buyback program
Risk Analysis
Downgraded on weak valued
Linked to NVS
PFE
24.85
+0.65%
AZN
83.22
-0.78%
MRK
87.62
+1.54%
SNY
49.66
-0.14%
LLY
799.57
-1.16%
Chart
$122.23 (+7.45%)
$116.66 (+12.58%)
$116.7 (+12.54%)
$109.38 (+20.08%)
NVS Analysts Opinion
NVS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Rating
Rating
Downgraded on weak valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Outperform the market
NVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
NVS Street view is extremely bullish and have positive views on the near-term outlook
NVS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
NVS Earnings
The TTM data reflects the most recent 12-month period, providing overview of NVS financial performance.
NVS Financial Health
The company financial health has moderately improved over the past year
Financial Score
NVS Latest Analysis
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial. On Friday NVS) shared results from the five-year analysis of the Phase 3 NATALEE .The data demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali (median follow-up: 58.4 months).Results showed a 28.4% reduction in risk of recurrence in patients with high-risk stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early ...
Fri Oct 17, 2025
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML. ® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph CML-CP) in all lines of treatment.12. In the trial Scemblix demonstrated superior major molecular response (MMR) rates when compared against all TKIs (imatinib nilotinib dasatinib and bosutinib) and also when compared against imatinib alone12. Patients treated w
Fri Oct 17, 2025
Novartis reports positive data from late-stage trial for Fabhalta.
Thu Oct 16, 2025
Novartis Strengthens Kidney Disease Pipeline With Promising Data. NVS) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta (iptacopan) in adults .NVS is in positive territory. IgA nephropathy also known as Berger'.s disease is an autoimmune kidney disease in which clumps of antibodies specifically immunoglobulin A (IgA) accumulate in the kidney'.s filters leading to inflammation and damage.Fabhalta statistically significant clinically meaningful sup
Thu Oct 16, 2025
NVS Reports Positive Late-Stage Data on Kidney Disease Drug . Novartis Fabhalta shows strong phase III results in slowing IgA nephropathy progression paving the way for full FDA approval in 2026.
Thu Oct 16, 2025
Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria. Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30 Novartis announced the US FDA approval of its drug Rhapsido (remibrutinib). This oral pill is approved for use in adult patients with chronic spontaneous urticaria/CSU whose symptoms persist despite treatment with H1 antihistamines. Rhapsido is a pill taken twice daily [….]
Mon Oct 13, 2025
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX.
Fri Oct 10, 2025
The Zacks Analyst Blog Highlights SAP Novartis Philip Morris International ImmuCell and ClearOne. SAPs cloud and AI push Novartis strong drug lineup and Philip Morris smoke-free growth headline Zacks latest analyst picks.
Thu Oct 9, 2025
Top Stock Reports for SAP Novartis & Philip Morris. SAP Novartis and Philip Morris headline todays top Zacks reports each showing strong momentum and strategic growth drivers despite industry headwinds.
Wed Oct 8, 2025
Heres Why Novartis (NVS) is a Strong Value Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Wed Oct 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.